Performance of laboratory tests used to measure blood phenylalanine for the monitoring of patients with phenylketonuria.
Ontology highlight
ABSTRACT: Analysis of blood phenylalanine is central to the monitoring of patients with phenylketonuria (PKU) and age-related phenylalanine target treatment-ranges (0-12 years; 120-360 μmol/L, and >12 years; 120-600 μmol/L) are recommended in order to prevent adverse neurological outcomes. These target treatment-ranges are based upon plasma phenylalanine concentrations. However, patients are routinely monitored using dried bloodspot (DBS) specimens due to the convenience of collection. Significant differences exist between phenylalanine concentrations in plasma and DBS, with phenylalanine concentrations in DBS specimens analyzed by flow-injection analysis tandem mass spectrometry reported to be 18% to 28% lower than paired plasma concentrations analyzed using ion-exchange chromatography. DBS specime
SUBMITTER: Moat SJ
PROVIDER: S-EPMC7957320 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA